February 18, 2005Journal of Clinical OncologyOpen Access

First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study

View Full Paper

Ask AI

Bookmark

Abstract

First and subsequent cycle use of pegfilgrastim with a moderately myelosuppressive chemotherapy regimen markedly reduced febrile neutropenia, febrile neutropenia-related hospitalizations, and IV anti-infective use.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vogel et al. (2005) studied this question.

synapsesocial.com/papers/69df4d6ed5404a0bea592e3b https://doi.org/10.1200/jco.2005.09.102

View Full Paper

Ask AI

Bookmark

First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study

Abstract

Discussion

Cite This Study

First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading